Gilead Sciences: Are Hepatitis C Sales Improving?
September 30, 2016 at 10:06 AM EDT
Citigroup's Robyn Karnauskas notes that Gilead Sciences' ( GILD ) hepatitis C prescriptions are " still below consensus but new starts contribute to improvement." She explains:
